JP2023520636A5 - - Google Patents
Info
- Publication number
- JP2023520636A5 JP2023520636A5 JP2022555860A JP2022555860A JP2023520636A5 JP 2023520636 A5 JP2023520636 A5 JP 2023520636A5 JP 2022555860 A JP2022555860 A JP 2022555860A JP 2022555860 A JP2022555860 A JP 2022555860A JP 2023520636 A5 JP2023520636 A5 JP 2023520636A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- chain variable
- variable region
- bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990281P | 2020-03-16 | 2020-03-16 | |
| US62/990,281 | 2020-03-16 | ||
| PCT/US2021/022626 WO2021188590A2 (en) | 2020-03-16 | 2021-03-16 | T-cell bispecific binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520636A JP2023520636A (ja) | 2023-05-18 |
| JP2023520636A5 true JP2023520636A5 (cg-RX-API-DMAC7.html) | 2024-03-21 |
Family
ID=77768281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555860A Pending JP2023520636A (ja) | 2020-03-16 | 2021-03-16 | T細胞二重特異性結合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230183344A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121462A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520636A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667314A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021239929A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3171709A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021188590A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024131861A1 (en) * | 2022-12-21 | 2024-06-27 | Erasmus University Medical Center Rotterdam | Bispecific antibodies targeting cd117 and cd3 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119241716B (zh) * | 2024-09-13 | 2026-05-19 | 杭州百瑞竞康生物技术有限公司 | 结合CD235a和CD3的融合蛋白及其制备方法和用途 |
| CN119874942B (zh) * | 2025-03-28 | 2025-09-26 | 核欣(苏州)医药科技有限公司 | 一种放射性蛋白偶联药物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| EP3105252B1 (en) * | 2014-02-12 | 2019-07-24 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| ES2823033T3 (es) * | 2015-05-28 | 2021-05-05 | Genentech Inc | Ensayo basado en células para detectar homodímeros anti-CD3 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
| IL258491B2 (en) * | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| EP3408671B1 (en) * | 2016-01-25 | 2023-11-01 | F. Hoffmann-La Roche AG | Methods for assaying t-cell dependent bispecific antibodies |
| US10538579B2 (en) * | 2016-08-15 | 2020-01-21 | Board Of Regents, The University Of Texas System | Bispecific pertussis antibodies |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| US10882915B2 (en) * | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) * | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CN113330026A (zh) * | 2018-10-23 | 2021-08-31 | 美真达治疗公司 | Fc沉默的抗体药物缀合物(ADC)及其用途 |
| GB201912681D0 (en) * | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
-
2021
- 2021-03-16 EP EP21771456.7A patent/EP4121462A4/en active Pending
- 2021-03-16 CA CA3171709A patent/CA3171709A1/en active Pending
- 2021-03-16 JP JP2022555860A patent/JP2023520636A/ja active Pending
- 2021-03-16 WO PCT/US2021/022626 patent/WO2021188590A2/en not_active Ceased
- 2021-03-16 CN CN202180035812.8A patent/CN115667314A/zh active Pending
- 2021-03-16 AU AU2021239929A patent/AU2021239929A1/en not_active Abandoned
- 2021-03-16 US US17/906,471 patent/US20230183344A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531141A5 (cg-RX-API-DMAC7.html) | ||
| US20230028110A1 (en) | Anti-tcr delta variable 1 antibodies | |
| US20230183344A1 (en) | T-cell bispecific binding proteins | |
| EP4269444B1 (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| US20220403025A1 (en) | Therapeutic uses of anti-tcr delta variable 1 antibodies | |
| JP2023515199A5 (cg-RX-API-DMAC7.html) | ||
| JP2023515199A (ja) | 免疫応答を調節するための材料及び方法 | |
| JP2022521850A5 (cg-RX-API-DMAC7.html) | ||
| US20210284731A1 (en) | Methods and materials for modulating an immune response | |
| JP2025507836A5 (cg-RX-API-DMAC7.html) | ||
| SG11202107474RA (en) | Anti-tigit antibodies | |
| JP2025507836A (ja) | 骨髄コンディショニング方法 | |
| Kobayashi et al. | Improved Biodistribution of 125I-labeled Anti-Tac Disulfide-stabilized Fv Fragment by Blocking Its Binding to the α Subunit of the Interleukin 2 Receptor in the Circulation with Preinjected Humanized Anti-Tac IgG | |
| EP4110390A1 (en) | Materials and methods for modulating an immune response | |
| HK40103002A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40103002B (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40103226A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40097714A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40102396A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| WO2024152962A1 (zh) | 抗tt3的人源化抗体及其应用 | |
| HK40103477A (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40102395B (en) | Multispecific anti-tcr delta variable 1 antibodies | |
| HK40102395A (en) | Multispecific anti-tcr delta variable 1 antibodies |